GPR35; GPBAR1; DRD4; | |
NPSR1; CXCR1; | |
ALPL; RECQL; PLA2G1B; TDP1; ALPI; APOBEC3G; PKM; PIK3CA; PIK3CG; PIK3CB; PIK3R1; GLO1; HPGD; PGD; MPO; AKR1B1; HSD17B2; HSD17B10; ALOX15; NQO2; AKR1B10; ALDH1A1; ALOX12; GFER; NOX4; USP2; PYGL; APEX1; POLB; CD38; | |
PTPN1; CDC25B; PTPN2; | |
ACHE; GAA; | |
HDAC3; | |
BCL2; | |
TOP2A; | |
NEK6; AKT1; MET; CAMK2B; BCR; INSR; CSNK2A1; DAPK1; SYK; AXL; NEK2; FLT3; MYLK; SRC; IGF1R; AURKB; GSK3B; CDK1; MAPK1; MAPK14; PIM1; NUAK1; ALK; PTK2; KDR; PKN1; | |
CA7; CA3; CA14; CA5B; CA12; CA9; CA13; CA4; CA6; CA2; CA1; CA5A; | |
NR1H4; | |
ESR1; ESR2; | |
KDM4E; | |
MAOA; ALOX5; PTGS1; PTGS2; XDH; | |
MMP13; MMP3; MMP2; MMP9; | |
BACE1; | |
STAT6; HIF1A; NFKB1; TP53; | |
ABCC1; ABCG2; | |
SLC6A2; SLCO1B3; SLCO1B1; | |
LMNA; MAPT; GMNN; THPO; HTT; RAB9A; NPC1; APP; | |
L3MBTL1; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 2 | CYP2A13 | Cytochrome P450 2A13 | Q16696 | CHEMBL3542436 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
Cytochrome P450 family 2 | CYP2C8 | Cytochrome P450 2C8 | P10632 | CHEMBL3721 |
Cytochrome P450 family 2 | CYP2A6 | Cytochrome P450 2A6 | P11509 | CHEMBL5282 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | PIK3CB | PI3-kinase p110-beta subunit | P42338 | CHEMBL3145 |
Enzyme_unclassified | PIK3R1 | PI3-kinase p85-alpha subunit | P27986 | CHEMBL2506 |
Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
Enzyme_unclassified | PGD | 6-phosphogluconate dehydrogenase | P52209 | CHEMBL3404 |
Enzyme_unclassified | MPO | Myeloperoxidase | P05164 | CHEMBL2439 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Enzyme_unclassified | NQO2 | Quinone reductase 2 | P16083 | CHEMBL3959 |
Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
Enzyme_unclassified | PYGL | Liver glycogen phosphorylase | P06737 | CHEMBL2568 |
Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Enzyme_unclassified | CD38 | Lymphocyte differentiation antigen CD38 | P28907 | CHEMBL4660 |
Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | ALPI | Intestinal alkaline phosphatase | P09923 | CHEMBL5573 |
Enzyme_unclassified | APOBEC3G | DNA dC->dU-editing enzyme APOBEC-3G | Q9HC16 | CHEMBL1741217 |
Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
Enzyme_unclassified | PIK3CA | PI3-kinase p110-alpha subunit | P42336 | CHEMBL4005 |
Enzyme_unclassified | PIK3CG | PI3-kinase p110-gamma subunit | P48736 | CHEMBL3267 |
Histone deacetylase | HDAC3 | Histone deacetylase 3 | O15379 | CHEMBL1829 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
Isomerase | TOP2A | DNA topoisomerase II alpha | P11388 | CHEMBL1806 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Lyase | CA13 | Carbonic anhydrase XIII | Q8N1Q1 | CHEMBL3912 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
Metallo protease | MMP13 | Matrix metalloproteinase 13 | P45452 | CHEMBL280 |
Metallo protease | MMP3 | Matrix metalloproteinase 3 | P08254 | CHEMBL283 |
Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
Miscellaneous ion channel | BCL2 | Apoptosis regulator Bcl-2 | P10415 | CHEMBL4860 |
Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
Peptide receptor (family A GPCR) | CXCR1 | Interleukin-8 receptor A | P25024 | CHEMBL4029 |
Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
Protein Kinase | ALK | ALK tyrosine kinase receptor | Q9UM73 | CHEMBL4247 |
Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | PKN1 | Protein kinase N1 | Q16512 | CHEMBL3384 |
Protein Kinase | NEK6 | Serine/threonine-protein kinase NEK6 | Q9HC98 | CHEMBL4309 |
Protein Kinase | AKT1 | Serine/threonine-protein kinase AKT | P31749 | CHEMBL4282 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | CAMK2B | CaM kinase II beta | Q13554 | CHEMBL4121 |
Protein Kinase | BCR | Bcr/Abl fusion protein | P11274 | CHEMBL2096618 |
Protein Kinase | INSR | Insulin receptor | P06213 | CHEMBL1981 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
Protein Kinase | SYK | Tyrosine-protein kinase SYK | P43405 | CHEMBL2599 |
Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
Protein Kinase | NEK2 | Serine/threonine-protein kinase NEK2 | P51955 | CHEMBL3835 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | MYLK | Myosin light chain kinase, smooth muscle | Q15746 | CHEMBL2428 |
Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
Protein Kinase | MAPK14 | MAP kinase p38 alpha | Q16539 | CHEMBL260 |
Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
Protein Phosphatase | PTPN2 | T-cell protein-tyrosine phosphatase | P17706 | CHEMBL3807 |
SLC superfamily of solute carriers | SLC6A2 | Norepinephrine transporter | P23975 | CHEMBL222 |
SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
Small molecule receptor (family A GPCR) | GPR35 | G-protein coupled receptor 35 | Q9HC97 | CHEMBL1293267 |
Small molecule receptor (family A GPCR) | GPBAR1 | G-protein coupled bile acid receptor 1 | Q8TDU6 | CHEMBL5409 |
Small molecule receptor (family A GPCR) | DRD4 | Dopamine D4 receptor | P21917 | CHEMBL219 |
Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Unclassified | GMNN | Geminin | O75496 | CHEMBL1293278 |
Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 4.354E-13 | 1.215E-10 | CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, CYP2C19, CYP2C8, CYP2C9 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.038E-12 | 2.723E-10 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2C8, CYP2D6, CYP3A4 |
MF | GO:0005488; binding | GO:0005524; ATP binding | 1.223E-12 | 3.070E-10 | ABCC1, ABCG2, AKT1, ALK, AURKB, AXL, BCR, CAMK2B, CDK1, CSNK2A1, DAPK1, FLT3, GSK3B, IGF1R, INSR, KDR, MAPK1, MAPK14, MET, MYLK, NEK2, NEK6, NUAK1, PIK3CA, PIK3CB, PIK3CG, PIM1, PKM, PKN1, PTK2, PYGL, RECQL, SRC, SYK, TOP2A, TP53 |
MF | GO:0003824; catalytic activity | GO:0004674; protein serine/threonine kinase activity | 1.063E-11 | 2.291E-09 | AKT1, ALK, AURKB, BCR, CAMK2B, CDK1, CSNK2A1, DAPK1, GSK3B, MAPK1, MAPK14, MYLK, NEK2, NEK6, NUAK1, PIK3CA, PIK3CG, PIM1, PKN1, SYK |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.274E-11 | 2.667E-09 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9 |
BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 1.710E-11 | 3.480E-09 | AURKB, CA2, CA7, HIF1A, HTT, MAPK1, MAPK14, NEK2, NPC1, NPSR1, NR1H4, PIK3CB, PLA2G1B, PTGS2, SYK |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 5.547E-11 | 9.459E-09 | CYP1A2, CYP2A6, CYP2C19, CYP2C8, CYP2C9, CYP3A4 |
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 5.561E-11 | 9.459E-09 | ALPI, APOBEC3G, CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESR1, ESR2, GLO1, L3MBTL1, MMP13, MMP2, MMP3, MMP9, NQO2, NR1H4, PTPN1, TP53 |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 6.001E-11 | 1.005E-08 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
BP | Unclassified; | GO:0032844; regulation of homeostatic process | 1.969E-10 | 2.909E-08 | AURKB, BCL2, CA2, CA7, CD38, HIF1A, HTT, KDR, MAPK1, MAPK14, NEK2, NPC1, NPSR1, NR1H4, PIK3CB, PLA2G1B, PTGS2, SRC, SYK |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.618E-09 | 1.894E-07 | CYP1A2, CYP2C8, CYP2C9, CYP3A4 |
BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 3.927E-09 | 4.385E-07 | AXL, INSR, MET, NOX4, PIK3CA, PIK3CB, PIK3CG, PIK3R1, PTK2, SRC, THPO |
MF | GO:0005488; binding | GO:0043560; insulin receptor substrate binding | 4.503E-09 | 4.903E-07 | IGF1R, INSR, PIK3CA, PIK3CB, PIK3R1 |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 7.680E-09 | 8.040E-07 | CYP1A2, CYP2C8, CYP2C9, CYP2D6, CYP3A4 |
BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 1.949E-08 | 1.912E-06 | AXL, KDR, MAPK14, PIK3CA, PIK3CB, PIK3R1, PTK2, SRC |
BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 3.698E-08 | 3.456E-06 | AKT1, BCL2, CAMK2B, CDK1, CSNK2A1, GSK3B, MAPK1, PKN1 |
BP | GO:0009987; cellular process | GO:0030168; platelet activation | 3.719E-08 | 3.461E-06 | AKT1, AXL, MAPK1, PIK3CA, PIK3CB, PIK3CG, PIK3R1, SRC, SYK |
BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 4.149E-08 | 3.781E-06 | ALOX12, ALOX15, ALOX5, HPGD, PTGS2 |
BP | GO:0008152; metabolic process | GO:0009804; coumarin metabolic process | 5.578E-08 | 4.938E-06 | CYP1A1, CYP2A13, CYP2A6, CYP2D6 |
MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 5.848E-08 | 5.135E-06 | CYP2A13, CYP2A6, CYP2C19, CYP2C8, CYP2C9 |
CC | GO:0044464; cell part | GO:0005829; cytosol | 1.826E-07 | 1.495E-05 | AKR1B1, AKR1B10, AKT1, ALDH1A1, ALOX12, ALOX15, ALOX5, APOBEC3G, APP, AURKB, BCL2, BCR, CA1, CA13, CA2, CA3, CA7, CAMK2B, CDC25B, CDK1, CSNK2A1, FLT3, GFER, GLO1, GMNN, GSK3B, HDAC3, HIF1A, HPGD, HTT, LMNA, MAPK1, MAPK14, MAPT, MYLK, NEK2, NEK6, NFKB1, NQO2, PGD, PIK3CA, PIK3CB, PIK3CG, PIK3R1, PIM1, PKM, PKN1, PLA2G1B, PTK2, PTPN1, PTPN2, PYGL, RAB9A, SRC, STAT6, SYK, TP53, XDH |
BP | GO:0009987; cellular process | GO:0043065; positive regulation of apoptotic process | 3.541E-07 | 2.803E-05 | AKT1, BCL2, CYP1B1, DAPK1, GSK3B, HPGD, HTT, MAPT, MMP9, NOX4, PIK3CB, PTGS2, PTPN2, SRC, TOP2A, TP53, XDH |
BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 5.365E-07 | 4.028E-05 | IGF1R, INSR, KDR, PTK2, SRC, SYK |
BP | GO:0032502; developmental process | GO:0001525; angiogenesis | 8.080E-07 | 5.924E-05 | CYP1B1, HIF1A, KDR, MAPK14, MMP2, PIK3CA, PIK3CB, PIK3CG, PTGS2, PTK2, SYK |
BP | GO:0065007; biological regulation | GO:0042593; glucose homeostasis | 8.751E-07 | 6.329E-05 | AKT1, HIF1A, INSR, NOX4, NR1H4, PIK3CA, PIK3R1, PTPN2, PYGL |
MF | GO:0005488; binding | GO:0051721; protein phosphatase 2A binding | 8.778E-07 | 6.329E-05 | AKT1, BCL2, MAPT, PTPN1, TP53 |
BP | GO:0048511; rhythmic process | GO:0048511; rhythmic process | 2.224E-06 | 1.459E-04 | AXL, BCL2, CSNK2A1, DRD4, ESR1, GSK3B, HDAC3, SRC, TOP2A, TP53, USP2 |
MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 2.558E-06 | 1.648E-04 | CYP1A1, CYP2C8, CYP3A4 |
BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 2.578E-06 | 1.651E-04 | AKR1B1, APEX1, AXL, CDK1, CYP1B1, STAT6 |
BP | GO:0009987; cellular process | GO:2001243; negative regulation of intrinsic apoptotic signaling pathway | 2.622E-06 | 1.675E-04 | AKT1, BCL2, HIF1A, MMP9, PTGS2, PTPN1, SRC |
BP | GO:0009987; cellular process | GO:2000811; negative regulation of anoikis | 2.774E-06 | 1.756E-04 | BCL2, PIK3CA, PTK2, SRC |
BP | GO:0051179; localization | GO:0042307; positive regulation of protein import into nucleus | 3.231E-06 | 2.016E-04 | APP, CDK1, HDAC3, MAPK1, MAPK14, PIK3R1, PTGS2 |
BP | GO:0022610; biological adhesion | GO:0001952; regulation of cell-matrix adhesion | 4.507E-06 | 2.749E-04 | BCL2, GSK3B, KDR, PIK3CB, PIK3R1, PTK2, SRC |
BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 4.807E-06 | 2.916E-04 | AKT1, BCL2, HIF1A, LMNA, PTGS2, SRC, TP53 |
BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 5.092E-06 | 3.046E-04 | CYP1A1, CYP2C8, CYP3A4 |
CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 6.431E-06 | 3.795E-04 | BCL2, CAMK2B, CDK1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, HSD17B2, NOX4, PTGS1, PTGS2, RAB9A |
CC | GO:0044464; cell part | GO:0005739; mitochondrion | 7.108E-06 | 4.146E-04 | AKT1, APEX1, BCL2, CA5A, CA5B, CDK1, CYP1A1, CYP1B1, CYP2D6, ESR2, GFER, GSK3B, HSD17B10, MAOA, MAPK1, MAPK14, MMP2, MPO, NFKB1, NOX4, PKM, SRC, TP53 |
BP | GO:0051179; localization | GO:0046326; positive regulation of glucose import | 7.960E-06 | 4.562E-04 | AKT1, INSR, MAPK14, NR1H4, PIK3R1 |
MF | GO:0003824; catalytic activity | GO:0035005; 1-phosphatidylinositol-4-phosphate 3-kinase activity | 8.869E-06 | 5.029E-04 | PIK3CA, PIK3CB, PIK3CG |
BP | GO:0050896; response to stimulus | GO:0071498; cellular response to fluid shear stress | 8.897E-06 | 5.032E-04 | CA2, HDAC3, PTGS2, SRC |
BP | GO:0032501; multicellular organismal process | GO:0043536; positive regulation of blood vessel endothelial cell migration | 8.935E-06 | 5.040E-04 | AKT1, HIF1A, KDR, MAPK14, PTGS2 |
BP | GO:0050896; response to stimulus | GO:0046626; regulation of insulin receptor signaling pathway | 1.529E-05 | 8.161E-04 | NR1H4, PIK3R1, PTPN1, PTPN2, SRC |
BP | GO:0008152; metabolic process | GO:1901575; organic substance catabolic process | 1.608E-05 | 8.478E-04 | ACHE, AKR1B10, AKT1, ALDH1A1, APOBEC3G, AURKB, BACE1, CDK1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2D6, CYP3A4, GAA, GSK3B, HSD17B10, MAOA, PKM, PLA2G1B, PYGL, TP53, USP2, XDH |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.270E-24 | 9.220E-21 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
CC | GO:0016020; membrane | GO:0045121; membrane raft | 1.970E-05 | 1.011E-03 | APP, BACE1, INSR, KDR, MAPK1, NPC1, PTGS2, SLC6A2, SRC, STAT6 |
BP | GO:0009987; cellular process | GO:0038096; Fc-gamma receptor signaling pathway involved in phagocytosis | 2.083E-05 | 1.062E-03 | MAPK1, PIK3CA, PIK3CB, PIK3R1, PTK2, SRC, SYK |
MF | GO:0005488; binding | GO:0032052; bile acid binding | 2.109E-05 | 1.068E-03 | NR1H4, PLA2G1B, PYGL |
MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 2.109E-05 | 1.068E-03 | INSR, KDR, SYK |
BP | GO:0032501; multicellular organismal process | GO:2000026; regulation of multicellular organismal development | 2.529E-05 | 1.250E-03 | AKT1, ALOX12, APP, AXL, BCL2, CA2, CAMK2B, CDK1, CYP1B1, ESR1, GSK3B, HIF1A, INSR, KDR, L3MBTL1, MAPK14, MAPT, NR1H4, PIK3R1, PIM1, PTGS2, PTK2, PTPN2, SRC, STAT6, SYK, THPO, XDH |
CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 2.840E-05 | 1.384E-03 | AKR1B1, AKT1, ALOX5, APEX1, AURKB, BCL2, CAMK2B, CDC25B, CDK1, CSNK2A1, ESR1, ESR2, GMNN, GSK3B, HDAC3, HIF1A, HPGD, HTT, L3MBTL1, LMNA, MAPK1, MAPK14, NEK2, NEK6, NFKB1, NQO2, NR1H4, NUAK1, PIM1, PKN1, POLB, PTPN2, RECQL, SRC, STAT6, TOP2A, TP53, USP2 |
MF | GO:0005488; binding | GO:0043548; phosphatidylinositol 3-kinase binding | 3.393E-05 | 1.628E-03 | AXL, IGF1R, INSR, PIK3R1 |
BP | GO:0065007; biological regulation | GO:0006874; cellular calcium ion homeostasis | 3.514E-05 | 1.682E-03 | APP, BCL2, CD38, DRD4, ESR1, GPR35, HTT, NPSR1, PIK3CB, PIK3CG, PLA2G1B |
BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 4.088E-05 | 1.898E-03 | APEX1, POLB |
BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 4.088E-05 | 1.898E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0004666; prostaglandin-endoperoxide synthase activity | 4.088E-05 | 1.898E-03 | PTGS1, PTGS2 |
MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 4.088E-05 | 1.898E-03 | ESR1, ESR2 |
MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 4.088E-05 | 1.898E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0008389; coumarin 7-hydroxylase activity | 4.088E-05 | 1.898E-03 | CYP2A13, CYP2A6 |
MF | GO:0005488; binding | GO:0034452; dynactin binding | 4.103E-05 | 1.901E-03 | GSK3B, HTT, MAPT |
BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 4.451E-05 | 2.045E-03 | AKT1, CYP1A2, MAPK1, MMP9 |
MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 5.062E-05 | 2.287E-03 | CSNK2A1, HIF1A, KDR, MAPT |
BP | GO:0009987; cellular process | GO:2001237; negative regulation of extrinsic apoptotic signaling pathway | 5.331E-05 | 2.398E-03 | AKT1, BCL2, DAPK1, HTT, LMNA, SRC |
BP | GO:0008283; cell proliferation | GO:0033598; mammary gland epithelial cell proliferation | 5.445E-05 | 2.445E-03 | ESR1, MAPK1, STAT6 |
BP | GO:0008152; metabolic process | GO:0010907; positive regulation of glucose metabolic process | 5.731E-05 | 2.531E-03 | AKT1, INSR, PTPN2, SRC |
BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 5.977E-05 | 2.618E-03 | BCL2, CA2, CA7, HTT, KDR, NPSR1, PLA2G1B, SRC |
BP | GO:0009987; cellular process | GO:0007569; cell aging | 6.103E-05 | 2.658E-03 | BCL2, CDK1, MAPK14, NOX4, TP53 |
BP | GO:0008152; metabolic process | GO:0006081; cellular aldehyde metabolic process | 6.103E-05 | 2.658E-03 | AKR1B10, ALDH1A1, CYP1B1, GLO1, PGD |
BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 6.262E-05 | 2.704E-03 | HIF1A, MMP13, MMP2, MMP3, MMP9, PLA2G1B |
MF | GO:0003824; catalytic activity | GO:0046934; phosphatidylinositol-4,5-bisphosphate 3-kinase activity | 6.569E-05 | 2.824E-03 | MET, PIK3CA, PIK3CB, PIK3CG, PIK3R1 |
MF | GO:0005488; binding | GO:0042826; histone deacetylase binding | 6.951E-05 | 2.962E-03 | GMNN, HDAC3, HIF1A, PKN1, TOP2A, TP53 |
MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 6.951E-05 | 2.962E-03 | AKR1B1, CYP19A1, CYP1A2, NOX4, NQO2, XDH |
BP | GO:0009987; cellular process | GO:1900103; positive regulation of endoplasmic reticulum unfolded protein response | 7.046E-05 | 2.985E-03 | PIK3R1, PTPN1, PTPN2 |
BP | GO:0065007; biological regulation | GO:0045124; regulation of bone resorption | 8.129E-05 | 3.361E-03 | CA2, CD38, SRC, SYK |
BP | GO:0051179; localization | GO:0030100; regulation of endocytosis | 8.572E-05 | 3.502E-03 | ALOX15, APP, AXL, BCR, PIK3CB, PTPN1, SRC, SYK |
BP | GO:0050896; response to stimulus | GO:0048545; response to steroid hormone | 8.572E-05 | 3.502E-03 | ALPL, BCL2, CA2, CD38, FLT3, NPC1, PTGS2, SRC |
MF | GO:0005488; binding | GO:0002039; p53 binding | 8.717E-05 | 3.554E-03 | GSK3B, HIF1A, HTT, NUAK1, TP53 |
BP | GO:0032502; developmental process | GO:0060065; uterus development | 8.926E-05 | 3.626E-03 | CYP19A1, ESR1, SRC |
BP | GO:0009987; cellular process | GO:0031334; positive regulation of protein complex assembly | 1.034E-04 | 4.093E-03 | ALOX15, ESR1, GSK3B, MAPT, MET, MMP3, SRC, TP53 |
BP | Unclassified; | GO:0044243; multicellular organismal catabolic process | 1.065E-04 | 4.195E-03 | MMP13, MMP2, MMP3, MMP9, PLA2G1B |
BP | GO:0009987; cellular process | GO:1903201; regulation of oxidative stress-induced cell death | 1.137E-04 | 4.420E-03 | AKT1, HIF1A, MET, MMP3, TP53 |
MF | GO:0003824; catalytic activity | GO:0016616; oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor | 1.190E-04 | 4.612E-03 | AKR1B1, AKR1B10, HPGD, HSD17B10, HSD17B2, PGD |
BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 1.221E-04 | 4.641E-03 | CYP2D6, CYP3A4 |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.221E-04 | 4.641E-03 | CA2, CA7 |
BP | GO:0019740; nitrogen utilization | GO:0006808; regulation of nitrogen utilization | 1.221E-04 | 4.641E-03 | BCL2, NR1H4 |
BP | GO:0009987; cellular process | GO:0038183; bile acid signaling pathway | 1.221E-04 | 4.641E-03 | GPBAR1, NR1H4 |
MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 1.221E-04 | 4.641E-03 | ALOX15, PTGS2 |
MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 1.221E-04 | 4.641E-03 | CYP1A1, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 1.221E-04 | 4.641E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 1.221E-04 | 4.641E-03 | ALOX12, ALOX15 |
MF | GO:0060089; molecular transducer activity | GO:0038181; bile acid receptor activity | 1.221E-04 | 4.641E-03 | GPBAR1, NR1H4 |
BP | GO:0022610; biological adhesion | GO:0033628; regulation of cell adhesion mediated by integrin | 1.236E-04 | 4.682E-03 | CYP1B1, PIK3CG, PTK2, SYK |
BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 1.290E-04 | 4.861E-03 | AXL, CDK1, CSNK2A1, FLT3, PKM |
BP | GO:0023052; signaling | GO:0050806; positive regulation of synaptic transmission | 1.305E-04 | 4.907E-03 | APP, CA2, CA7, DRD4, MAPK1, PTGS2 |
BP | GO:0009987; cellular process | GO:0050714; positive regulation of protein secretion | 1.396E-04 | 5.179E-03 | ACHE, CD38, HIF1A, MAPK14, NR1H4, PLA2G1B, SRC, SYK |
BP | GO:0009987; cellular process | GO:1901796; regulation of signal transduction by p53 class mediator | 1.423E-04 | 5.268E-03 | AKT1, AURKB, CSNK2A1, L3MBTL1, MAPK14, NUAK1, TP53 |
MF | GO:0003824; catalytic activity | GO:0004712; protein serine/threonine/tyrosine kinase activity | 1.499E-04 | 5.487E-03 | AKT1, AURKB, MAPK1, MAPK14 |
BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 1.644E-04 | 5.950E-03 | AURKB, MAPK1, NEK2 |
MF | GO:0003824; catalytic activity | GO:0035173; histone kinase activity | 1.644E-04 | 5.950E-03 | AURKB, CDK1, PKN1 |
BP | GO:0009987; cellular process | GO:0000226; microtubule cytoskeleton organization | 1.734E-04 | 6.242E-03 | AURKB, CDK1, HDAC3, HTT, LMNA, MAPT, NEK2, NEK6, PTK2 |
MF | GO:0005488; binding | GO:0042803; protein homodimerization activity | 1.772E-04 | 6.328E-03 | ABCG2, ACHE, AKT1, APOBEC3G, BCL2, CAMK2B, FLT3, HPGD, MAPT, NFKB1, NQO2, PTGS2, PYGL, TOP2A, XDH |
MF | GO:0003824; catalytic activity | GO:0016903; oxidoreductase activity, acting on the aldehyde or oxo group of donors | 1.801E-04 | 6.375E-03 | AKR1B1, AKR1B10, ALDH1A1, XDH |
BP | GO:0009987; cellular process | GO:0060326; cell chemotaxis | 1.810E-04 | 6.388E-03 | ABCC1, CXCR1, PIK3CA, PIK3CB, PIK3CG, PLA2G1B, SYK |
BP | GO:0009987; cellular process | GO:2000106; regulation of leukocyte apoptotic process | 1.848E-04 | 6.512E-03 | AURKB, AXL, HIF1A, PIK3CB, TP53 |
BP | GO:0009987; cellular process | GO:0090199; regulation of release of cytochrome c from mitochondria | 1.966E-04 | 6.873E-03 | AKT1, LMNA, MMP9, TP53 |
CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 2.000E-04 | 6.980E-03 | ABCC1, CA2, CA4, CA9, HPGD, SLCO1B1, SLCO1B3 |
BP | Unclassified; | GO:0042993; positive regulation of transcription factor import into nucleus | 2.143E-04 | 7.431E-03 | APP, HDAC3, PIK3R1, PTGS2 |
BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 2.311E-04 | 7.926E-03 | HIF1A, MMP13, MMP2, MMP3, MMP9 |
MF | GO:0005488; binding | GO:0005496; steroid binding | 2.311E-04 | 7.926E-03 | CYP3A4, ESR1, ESR2, NPC1, NR1H4 |
BP | GO:0008152; metabolic process | GO:0045862; positive regulation of proteolysis | 2.351E-04 | 8.023E-03 | AKT1, APP, CDK1, DAPK1, GSK3B, MAPK14, MAPT, PTK2, SRC, XDH |
BP | GO:0009987; cellular process | GO:1902202; regulation of hepatocyte growth factor receptor signaling pathway | 2.432E-04 | 8.173E-03 | PTPN1, PTPN2 |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 2.432E-04 | 8.173E-03 | CYP1A1, CYP1A2 |
MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 2.432E-04 | 8.173E-03 | ESR1, ESR2 |
MF | GO:0005488; binding | GO:0051425; PTB domain binding | 2.432E-04 | 8.173E-03 | APP, INSR |
BP | GO:0032501; multicellular organismal process | GO:0051241; negative regulation of multicellular organismal process | 2.448E-04 | 8.202E-03 | ALOX12, APP, AXL, BCL2, BCR, CD38, GPR35, GSK3B, HIF1A, LMNA, NFKB1, NR1H4, PIK3CG, PIK3R1, PTGS2, PTK2, PTPN2, XDH |
BP | GO:0002376; immune system process | GO:0002521; leukocyte differentiation | 2.849E-04 | 9.401E-03 | AXL, BCL2, FLT3, GLO1, MAPK14, MMP9, PIK3R1, PTPN2 |
BP | GO:0050896; response to stimulus | GO:0071320; cellular response to cAMP | 2.965E-04 | 9.680E-03 | APEX1, APP, NOX4, PIK3CG |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 5.039E-17 | 4.220E-14 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
MF | GO:0005488; binding | GO:0020037; heme binding | 1.572E-16 | 1.141E-13 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, MPO, NOX4, PTGS1, PTGS2, SRC |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 2.546E-16 | 1.732E-13 | CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 4.097E-15 | 1.784E-12 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, NOX4 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.118E-13 | 3.744E-11 | ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, XDH |
Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|
hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.127E-23 | 2.163E-21 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14; CA13 |
hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 4.884E-16 | 4.688E-14 | CAMK2B; SRC; MMP2; PIK3R1; PIK3CB; MAPK14; HIF1A; ESR1; MMP9; PTK2; PIK3CG; IGF1R; PIK3CA; KDR; AKT1; MAPK1; TP53; MET |
hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 2.103E-14 | 1.346E-12 | GSK3B; PIK3CA; SRC; AKT1; MAPK1; PIK3CB; PIK3R1; MAPK14; ESR1; NFKB1; ESR2; PIK3CG |
hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 1.066E-13 | 5.115E-12 | PIK3CA; SRC; KDR; AKT1; MAPK1; PIK3CB; PIK3R1; MAPK14; PTGS2; PTK2; PIK3CG |
hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 5.102E-13 | 1.633E-11 | GSK3B; FLT3; DAPK1; MMP2; PIK3CB; PIK3R1; PTGS2; HIF1A; MMP9; NFKB1; PIK3CG; PTK2; IGF1R; BCR; PIK3CA; BCL2; AKT1; MAPK1; MET; TP53 |
hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 3.175E-13 | 1.219E-11 | PKM; PIK3CA; FLT3; AKT1; MAPK1; PIK3CB; PIK3R1; TP53; MET; HIF1A; PIK3CG |
hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 1.782E-12 | 4.887E-11 | CAMK2B; PIK3CA; INSR; BCL2; AKT1; MAPK1; PIK3R1; PIK3CB; HIF1A; NFKB1; PIK3CG; IGF1R |
hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 8.048E-12 | 1.717E-10 | GSK3B; PIK3CA; BCL2; AKT1; MAPK1; PIK3CB; PIK3R1; TP53; NFKB1; PIK3CG; IGF1R |
hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 4.912E-12 | 1.179E-10 | CYP2C9; APP; CYP2C8; CYP2D6; MAOA; ALOX5; ALOX15; MAPK1; ALOX12; CYP2C19; PTGS2; PTGS1 |
hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 9.196E-12 | 1.766E-10 | GSK3B; HDAC3; PIK3CA; SRC; AKT1; MAPK1; PIK3R1; PIK3CB; TP53; ESR1; HIF1A; PIK3CG |
hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 1.125E-11 | 1.963E-10 | CAMK2B; GSK3B; PIK3CA; BCL2; AKT1; MAPK1; PIK3R1; PIK3CB; MAPK14; TP53; NFKB1; PIK3CG |
hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 3.867E-11 | 4.640E-10 | GSK3B; SYK; INSR; PIK3R1; PIK3CB; PTK2; NFKB1; PIK3CG; IGF1R; PIK3CA; KDR; BCL2; AKT1; MAPK1; PKN1; TP53; MET |
hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 3.291E-11 | 4.212E-10 | PIK3CA; MMP2; PIM1; BCL2; AKT1; MAPK1; PIK3R1; PIK3CB; MAPK14; NFKB1; PIK3CG |
hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 3.002E-11 | 4.117E-10 | GSK3B; SYK; CSNK2A1; PIK3R1; PIK3CB; MAPK14; NFKB1; PIK3CG; PIK3CA; BCL2; CDK1; AKT1; CD38; TP53 |
hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 2.637E-11 | 4.117E-10 | PIK3CA; SRC; MMP2; AKT1; MAPK1; PIK3R1; PIK3CB; ESR1; MMP9; ESR2; PIK3CG |
hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 3.002E-11 | 4.117E-10 | GSK3B; SRC; PIK3R1; PIK3CB; PTK2; PIK3CG; MYLK; IGF1R; PIK3CA; KDR; BCL2; AKT1; MAPK1; MET |
hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 8.423E-11 | 8.617E-10 | PIK3CA; MMP3; AKT1; MAPK1; PIK3R1; PIK3CB; MAPK14; PTGS2; MMP9; NFKB1; PIK3CG |
hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 1.147E-10 | 1.101E-09 | PIK3CA; SRC; BCL2; AKT1; MAPK1; STAT6; PIK3R1; PIK3CB; TP53; MMP9; NFKB1; PIK3CG |
hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 7.065E-11 | 7.979E-10 | PIK3CA; FLT3; PIM1; AKT1; MAPK1; PIK3CB; PIK3R1; NFKB1; PIK3CG |
hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 1.382E-10 | 1.243E-09 | PIK3CA; BCL2; AKT1; PIK3CB; PIK3R1; PTGS2; TP53; NFKB1; PTK2; PIK3CG |
hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 1.554E-10 | 1.243E-09 | CAMK2B; GSK3B; PIK3CA; SRC; AKT1; MAPK1; PIK3CB; PIK3R1; PTK2; PIK3CG |
hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 4.763E-10 | 3.153E-09 | HDAC3; SYK; SRC; PIK3R1; PIK3CB; NFKB1; PIK3CG; POLB; PKM; PIK3CA; CDK1; MAPK1; TP53 |
hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 2.605E-10 | 1.852E-09 | PIK3CA; SYK; SRC; AKT1; MAPK1; PIK3R1; PIK3CB; MAPK14; PIK3CG; MYLK; PTGS1 |
hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 8.528E-11 | 8.617E-10 | CYP2C9; CYP2C8; CYP2A6; CYP2A13; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19; PTGS2 |
hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 1.552E-10 | 1.243E-09 | GSK3B; PIK3CA; BCL2; AKT1; MAPK1; PIK3CB; PIK3R1; TP53; PIK3CG |
hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 2.177E-10 | 1.672E-09 | ABCC1; PIK3CA; BCL2; AKT1; MAPK1; PIK3R1; PIK3CB; MAPK14; TP53; NFKB1; PIK3CG |
hsa05214 | Glioma_Homo sapiens_hsa05214 | 2.408E-10 | 1.778E-09 | CAMK2B; PIK3CA; AKT1; MAPK1; PIK3CB; PIK3R1; TP53; PIK3CG; IGF1R |
hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 1.552E-10 | 1.243E-09 | CYP2C9; CYP2C8; PLA2G1B; ALOX5; ALOX15; ALOX12; CYP2C19; PTGS2; PTGS1 |
hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 5.137E-10 | 3.288E-09 | PIK3CA; CDK1; AKT1; MAPK1; PIK3R1; PIK3CB; MAPK14; PIK3CG; CDC25B; IGF1R |
hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 1.732E-09 | 8.988E-09 | PLA2G1B; MAOA; ALOX15; AKR1B1; ALOX12; PYGL; PTGS2; CYP2C19; CYP3A4; CYP19A1; HSD17B10; PTGS1; ALOX5; HSD17B2; CD38; XDH; GAA; PGD; CYP2C9; CYP2C8; CYP2A6; PKM; AKR1B10; CYP1A2; ALDH1A1; CYP1A1; ALPL; ALPI |
hsa05218 | Melanoma_Homo sapiens_hsa05218 | 5.439E-10 | 3.369E-09 | PIK3CA; AKT1; MAPK1; PIK3CB; PIK3R1; TP53; MET; PIK3CG; IGF1R |
hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 7.017E-10 | 4.082E-09 | BCR; PIK3CA; AKT1; MAPK1; PIK3CB; PIK3R1; TP53; NFKB1; PIK3CG |
hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 7.017E-10 | 4.082E-09 | GSK3B; PIK3CA; SYK; AKT1; MAPK1; PIK3CB; PIK3R1; NFKB1; PIK3CG |
hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 1.477E-09 | 7.877E-09 | PTPN1; GSK3B; PIK3CA; INSR; AKT1; PIK3R1; PIK3CB; PYGL; NFKB1; PIK3CG |
hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 3.222E-09 | 1.546E-08 | PIK3CA; ALOX5; BCL2; AKT1; MAPK1; PIK3R1; PIK3CB; MAPK14; NFKB1; PIK3CG |
hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 7.859E-09 | 3.429E-08 | PIK3CA; SRC; INSR; KDR; AKT1; MAPK1; PIK3R1; PIK3CB; MAPK14; MET; PIK3CG; IGF1R |
hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 6.894E-09 | 3.229E-08 | PIK3CA; INSR; AKT1; PIK3CB; PIK3R1; TP53; NFKB1; PIK3CG; IGF1R |
hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 1.032E-08 | 4.307E-08 | GSK3B; PIK3CA; AKT1; MAPK1; PIK3R1; PIK3CB; MAPK14; TP53; NFKB1; PIK3CG |
hsa05162 | Measles_Homo sapiens_hsa05162 | 1.280E-08 | 5.119E-08 | GSK3B; PIK3CA; CSNK2A1; AKT1; RAB9A; PIK3R1; PIK3CB; TP53; NFKB1; PIK3CG |
hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.692E-08 | 6.246E-08 | PIK3CA; LMNA; BCL2; AKT1; MAPK1; PIK3R1; PIK3CB; TP53; NFKB1; PIK3CG |
hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 1.779E-08 | 6.324E-08 | PIK3CA; PLA2G1B; INSR; KDR; AKT1; MAPK1; PIK3R1; PIK3CB; MET; NFKB1; PIK3CG; IGF1R |
hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 1.041E-09 | 5.710E-09 | GSK3B; PIK3CA; AKT1; MAPK1; PIK3CB; PIK3R1; TP53; PIK3CG |
hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 1.579E-08 | 6.187E-08 | PTPN1; GSK3B; PIK3CA; INSR; AKT1; MAPK1; PIK3R1; PIK3CB; PYGL; PIK3CG |
hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 1.925E-09 | 9.475E-09 | ALK; PIK3CA; AKT1; MAPK1; PIK3CB; PIK3R1; TP53; PIK3CG |
hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 7.503E-10 | 4.237E-09 | ALOX5; INSR; HSD17B2; CYP1A1; CYP1B1; PTGS2; CYP19A1; IGF1R |
hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 7.390E-09 | 3.300E-08 | PIK3CA; AKT1; MAPK1; PIK3CB; PIK3R1; TP53; NFKB1; PIK3CG |
hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 2.403E-08 | 8.388E-08 | GSK3B; PIK3CA; CXCR1; SRC; AKT1; MAPK1; PIK3R1; PIK3CB; NFKB1; PTK2; PIK3CG |
hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 1.925E-09 | 9.475E-09 | PIK3CA; INSR; AKT1; PIK3CB; PIK3R1; PTGS2; PIK3CG; PTGS1 |
hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 9.413E-09 | 4.016E-08 | PIK3CA; SYK; AKT1; MAPK1; PIK3CB; PIK3R1; MAPK14; PIK3CG |
hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 1.691E-08 | 6.246E-08 | GSK3B; PIK3CA; AKT1; MAPK1; PIK3R1; PIK3CB; MAPK14; NFKB1; PIK3CG |
hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 2.999E-08 | 1.028E-07 | CAMK2B; ACHE; PIK3CA; BCL2; AKT1; MAPK1; PIK3R1; PIK3CB; PIK3CG |
hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 5.365E-08 | 1.776E-07 | CAMK2B; PIK3CA; SRC; CD38; MAPK1; PIK3R1; PIK3CB; PTGS2; PIK3CG; MYLK |
hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 5.365E-08 | 1.776E-07 | PIK3CA; THPO; PIM1; BCL2; AKT1; STAT6; PIK3R1; PIK3CB; PTPN2; PIK3CG |
hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 7.390E-09 | 3.300E-08 | PIK3CA; AKT1; MAPK1; PIK3CB; PIK3R1; MET; HIF1A; PIK3CG |
hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 1.350E-07 | 4.297E-07 | PIK3CA; SYK; AKT1; MAPK1; PIK3R1; PIK3CB; MAPK14; NFKB1; PIK3CG |
hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.059E-08 | 4.327E-08 | CYP2C9; CYP2C8; CYP2A6; MAOA; CYP2D6; CYP1A2; CYP3A4; CYP2C19 |
hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 1.441E-07 | 4.391E-07 | PIK3CA; INSR; AKT1; MAPK1; PIK3R1; PIK3CB; MAPK14; PIK3CG; IGF1R |
hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 1.827E-07 | 5.315E-07 | HPGD; FLT3; MMP3; TP53; MPO; MMP9; MET; NFKB1; PTK2; IGF1R |
hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.668E-08 | 6.246E-08 | CYP2C9; CYP2A6; CYP2A13; CYP2D6; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 3.337E-07 | 8.899E-07 | ABCC1; PIK3CA; PIM1; BCL2; CYP1B1; MAPK1; PTGS2; TP53; MMP9; MET; NFKB1; CDC25B |
hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 2.524E-07 | 7.126E-07 | GSK3B; PIK3CA; AKT1; MAPK1; PIK3R1; PIK3CB; MAPK14; PIK3CG; IGF1R |
hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 1.716E-07 | 5.070E-07 | CAMK2B; PIK3CA; SRC; ALOX12; PIK3R1; PIK3CB; MAPK14; PIK3CG |
hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 2.843E-07 | 7.799E-07 | PIK3CA; SYK; CXCR1; INSR; AKT1; MAPK1; PIK3R1; PIK3CB; PIK3CG |
hsa04261 | Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | 3.589E-07 | 9.439E-07 | CAMK2B; PIK3CA; BCL2; AKT1; MAPK1; PIK3R1; PIK3CB; MAPK14; PIK3CG |
hsa05164 | Influenza A_Homo sapiens_hsa05164 | 1.466E-06 | 3.655E-06 | GSK3B; PIK3CA; AKT1; MAPK1; PIK3R1; PIK3CB; MAPK14; NFKB1; PIK3CG |
hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 3.156E-07 | 8.536E-07 | PIK3CA; AKT1; MAPK1; PIK3R1; PIK3CB; MAPK14; NFKB1; PIK3CG |
hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 2.724E-07 | 7.579E-07 | PIK3CA; AKT1; MAPK1; PIK3R1; PIK3CB; MAPK14; NFKB1; PIK3CG |
hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 4.137E-10 | 2.837E-09 | CYP2C9; CYP2C8; PLA2G1B; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 4.607E-06 | 1.079E-05 | GSK3B; PIK3CA; INSR; AKT1; PIK3R1; PIK3CB; NFKB1; PIK3CG |
hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 3.359E-05 | 7.329E-05 | POLB; GSK3B; PIK3CA; AKT1; PIK3R1; PIK3CB; TP53; NFKB1; PIK3CG |
hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 7.197E-07 | 1.818E-06 | PIK3CA; MMP2; PIK3R1; PIK3CB; MAPK14; MMP9; PTK2; PIK3CG |
hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 9.672E-06 | 2.185E-05 | PIK3CA; INSR; AKT1; MAPK1; PIK3R1; PIK3CB; PIK3CG; MYLK |
hsa04810 | Regulation of actin cytoskeleton_Homo sapiens_hsa04810 | 5.734E-05 | 1.210E-04 | PIK3CA; SRC; MAPK1; PIK3R1; PIK3CB; PTK2; PIK3CG; MYLK |
hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 1.539E-05 | 3.396E-05 | CAMK2B; SYK; SRC; BCL2; AKT1; MAPK1; MAPK14; NFKB1 |
hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 3.429E-05 | 7.396E-05 | CAMK2B; PIK3CA; AKT1; MAPK1; PIK3R1; PIK3CB; NFKB1; PIK3CG |
hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 1.071E-03 | 2.036E-03 | AKT1; MAPK1; MAPT; MAPK14; TP53; NFKB1; CDC25B |
hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 8.732E-08 | 2.842E-07 | PIK3CA; AKT1; MAPK1; PIK3CB; PIK3R1; HIF1A; PIK3CG |
hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 1.376E-07 | 4.297E-07 | PIK3CA; INSR; AKT1; PIK3CB; PIK3R1; PIK3CG; IGF1R |
hsa04144 | Endocytosis_Homo sapiens_hsa04144 | 2.274E-02 | 3.492E-02 | CXCR1; SRC; KDR; MET; IGF1R |
hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 3.153E-06 | 7.473E-06 | PIK3CA; AKT1; MAPK1; PIK3R1; PIK3CB; HIF1A; PIK3CG |
hsa04060 | Cytokine-cytokine receptor interaction_Homo sapiens_hsa04060 | 2.479E-02 | 3.746E-02 | CXCR1; THPO; FLT3; KDR; MET |
hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 6.336E-04 | 1.241E-03 | BACE1; APP; GSK3B; MAPK1; MAPT; HSD17B10 |
hsa04152 | AMPK signaling pathway_Homo sapiens_hsa04152 | 1.227E-05 | 2.739E-05 | PIK3CA; INSR; AKT1; PIK3R1; PIK3CB; PIK3CG; IGF1R |
hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 2.821E-02 | 4.167E-02 | CSNK2A1; CDK1; TP53; NFKB1 |
hsa04650 | Natural killer cell mediated cytotoxicity_Homo sapiens_hsa04650 | 1.969E-04 | 3.979E-04 | PIK3CA; SYK; MAPK1; PIK3R1; PIK3CB; PIK3CG |
hsa04666 | Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | 1.809E-06 | 4.396E-06 | PIK3CA; SYK; AKT1; MAPK1; PIK3CB; PIK3R1; PIK3CG |
hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 1.185E-02 | 1.945E-02 | CAMK2B; GSK3B; CSNK2A1; TP53 |
hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 7.249E-03 | 1.265E-02 | CAMK2B; CDK1; MAPK1; IGF1R |
hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 7.455E-03 | 1.290E-02 | GSK3B; CDK1; TP53; CDC25B |
hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 1.536E-04 | 3.138E-04 | CAMK2B; GSK3B; MAOA; AKT1; MAPK14; DRD4 |
hsa04360 | Axon guidance_Homo sapiens_hsa04360 | 8.098E-03 | 1.388E-02 | GSK3B; MAPK1; MET; PTK2 |
hsa04916 | Melanogenesis_Homo sapiens_hsa04916 | 2.434E-02 | 3.709E-02 | CAMK2B; GSK3B; MAPK1 |
hsa04922 | Glucagon signaling pathway_Homo sapiens_hsa04922 | 3.617E-03 | 6.490E-03 | CAMK2B; PKM; AKT1; PYGL |
hsa04070 | Phosphatidylinositol signaling system_Homo sapiens_hsa04070 | 3.246E-03 | 5.935E-03 | PIK3CA; PIK3R1; PIK3CB; PIK3CG |
hsa04972 | Pancreatic secretion_Homo sapiens_hsa04972 | 2.189E-02 | 3.389E-02 | CA2; PLA2G1B; CD38 |
hsa04723 | Retrograde endocannabinoid signaling_Homo sapiens_hsa04723 | 2.497E-02 | 3.746E-02 | MAPK1; MAPK14; PTGS2 |
hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 3.726E-05 | 7.949E-05 | PIK3CA; PIK3R1; PIK3CB; NFKB1; PTK2; PIK3CG |
hsa04640 | Hematopoietic cell lineage_Homo sapiens_hsa04640 | 1.742E-02 | 2.764E-02 | THPO; FLT3; CD38 |
hsa04540 | Gap junction_Homo sapiens_hsa04540 | 1.742E-02 | 2.764E-02 | SRC; CDK1; MAPK1 |
hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 2.567E-04 | 5.133E-04 | CAMK2B; SRC; MMP2; MAPK1; MAPK14 |
hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.534E-07 | 4.603E-07 | CYP2C9; CYP2C8; CYP2A6; CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 5.447E-07 | 1.394E-06 | PIK3CA; SRC; PIK3CB; PIK3R1; MET; PTK2; PIK3CG |
hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 2.840E-04 | 5.622E-04 | SYK; CSNK2A1; BCL2; PTGS2; NFKB1 |
hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 2.020E-03 | 3.765E-03 | MAPK1; PKN1; MAPK14; NFKB1 |
hsa04971 | Gastric acid secretion_Homo sapiens_hsa04971 | 1.095E-02 | 1.828E-02 | CAMK2B; CA2; MYLK |
hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 3.787E-07 | 9.826E-07 | PTPN1; CSNK2A1; SRC; INSR; MAPK1; MET; IGF1R |
hsa05133 | Pertussis_Homo sapiens_hsa05133 | 1.136E-02 | 1.880E-02 | MAPK1; MAPK14; NFKB1 |
hsa00562 | Inositol phosphate metabolism_Homo sapiens_hsa00562 | 9.786E-03 | 1.648E-02 | PIK3CA; PIK3CB; PIK3CG |
hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 1.770E-08 | 6.324E-08 | PKM; PIK3CA; INSR; MAPK1; PIK3CB; PIK3R1; PIK3CG |
hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 1.101E-03 | 2.073E-03 | MAPK1; MAPK14; PTGS2; NFKB1 |
hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 5.182E-06 | 1.199E-05 | SLCO1B1; CA2; SLCO1B3; NR1H4; CYP3A4; ABCG2 |
hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 5.334E-03 | 9.395E-03 | MAPK1; MAPK14; NFKB1 |
hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 7.116E-04 | 1.380E-03 | SRC; MAPK1; MAPK14; NFKB1 |
hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 6.444E-05 | 1.345E-04 | CXCR1; SRC; MAPK14; MET; NFKB1 |
hsa05014 | Amyotrophic lateral sclerosis (ALS)_Homo sapiens_hsa05014 | 3.900E-03 | 6.933E-03 | BCL2; MAPK14; TP53 |
hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 3.045E-02 | 4.463E-02 | ABCC1; ABCG2 |
hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 1.564E-06 | 3.849E-06 | CYP1A2; HSD17B2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 2.907E-03 | 5.367E-03 | CYP2A6; CYP3A4; XDH |
hsa04960 | Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | 1.388E-07 | 4.297E-07 | PIK3CA; INSR; MAPK1; PIK3CB; PIK3R1; PIK3CG |
hsa00620 | Pyruvate metabolism_Homo sapiens_hsa00620 | 2.551E-02 | 3.797E-02 | PKM; GLO1 |
hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 1.388E-02 | 2.258E-02 | MAPK1; TP53 |
hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 1.893E-07 | 5.425E-07 | DAPK1; SRC; MMP2; MAPK1; MMP9; TP53 |
hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 1.675E-02 | 2.703E-02 | AKR1B10; AKR1B1 |
hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 2.094E-02 | 3.268E-02 | AKR1B10; AKR1B1 |
hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 1.776E-02 | 2.795E-02 | POLB; APEX1 |
hsa04973 | Carbohydrate digestion and absorption_Homo sapiens_hsa04973 | 8.463E-06 | 1.934E-05 | PIK3CA; AKT1; PIK3CB; PIK3R1; PIK3CG |
hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 8.357E-04 | 1.604E-03 | AKR1B10; GAA; AKR1B1 |
hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 1.082E-04 | 2.234E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 8.860E-03 | 1.505E-02 | CA2; CA4 |
hsa00790 | Folate biosynthesis_Homo sapiens_hsa00790 | 3.305E-03 | 5.986E-03 | ALPL; ALPI |
hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 2.305E-06 | 5.533E-06 | CYP2A6; CYP1A2; XDH |
ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
---|---|---|---|
E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5; PTGS2 |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2; KDR |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; AXL; PTGS2; IGF1R; IGF1R; KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | INSR |
C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | SYK; PIK3CG; PIK3CG |
A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R |
A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
C00-D49: Neoplasms | Gastric cancer | C16 | KDR; KDR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5; SYK; PIK3CB |
C00-D49: Neoplasms | Thyroid cancer | C73 | KDR |
C00-D49: Neoplasms | Glioma | C71 | PIK3CG; KDR; APP |
C00-D49: Neoplasms | Ocular cancer | C69 | APEX1 |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; SLC6A2 |
NA: NA | Colour dead tissues | NA | PTPN1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA; SLC6A2; SLC6A2; SLC6A2; SLC6A2 |
I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
H00-H59: Diseases of the eye and adnexa | Diabetic retinopathy | H36, E10.3, E11.3, E13.3 | MAPK14 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; PTGS1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6; CA2 |
C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | PIK3CG; KDR |
C00-D49: Neoplasms | Osteosarcoma | C40-C41 | GSK3B; SRC |
C00-D49: Neoplasms | Brain cancer | C71, D33 | SRC; ESR1 |
C00-D49: Neoplasms | Multiple myeloma | C90 | SRC; IGF1R; CD38; BCL2 |
G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | MPO; ESR1; ESR1 |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypoglycemia | E16.0-E16.2 | INSR |
C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | INSR |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MPO; MAOA; ACHE |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
NA: NA | Enthesopathy | NA | PIK3CG |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Erectile dysfunction | F52.2, N48.4 | DRD4 |
A00-B99: Certain infectious and parasitic diseases | Infections disease | A00-B99 | MPO |
A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
NA: NA | Miosis during ocular surgery | NA | PTGS1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | DRD4 |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
NA: NA | Upper abdominal bloating | NA | ACHE |
C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CAMK2B; AKR1B1; PLA2G1B; ALOX5; SYK; MMP3; PTGS2; PTGS2; PTGS2; PTGS2; MAPK14 |
J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
NA: NA | Rheumatold arthritis | NA | PTGS1; PTGS2; PTGS2; PTGS2; MAPK14 |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR |
G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD4 |
E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
NA: NA | Postmenopausal disorder | NA | ESR1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |
C00-D49: Neoplasms | B-cell lymphoma | C85.1 | SYK |
C00-D49: Neoplasms | Solid tumours | C00-D48 | AKT1; MET; PKM; SYK; PIK3CA; PIK3CG; FLT3; CA9; MMP2; SRC; IGF1R; AURKB; HIF1A; MAPK1; MMP9; PTK2; TP53; PIK3CB; KDR; KDR; KDR; TOP2A |
A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5; RAB9A |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | SLC6A2 |
N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; PTGS1; IGF1R; MMP9; TP53; KDR |
C00-D49: Neoplasms | Colon cancer | C50 | ALPL; FLT3 |
K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B |
A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | PIK3CG; CYP2C9 |
L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | SLC6A2; SLC6A2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | SYK; INSR; ESR1 |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R |
H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | SLC6A2 |
I00-I99: Diseases of the circulatory system | Coronary artery disease | I20-I25 | MAPK14; MAPK14 |
Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1 |
H00-H59: Diseases of the eye and adnexa | Corneal ulcers | H16.0 | MMP3 |
I00-I99: Diseases of the circulatory system | Ischemic stroke | I61-I63 | MMP3 |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B; ABCC1; ALOX5; PIK3CG; PTGS2; PTGS2; MAPK14 |
I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PIK3CA; PTK2; TP53 |
L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
C00-D49: Neoplasms | Prostate cancer | C61 | PIK3CG; FLT3; BCL2; ESR1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B; ALOX5 |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3; MAPK14; BCL2 |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | FLT3; FLT3; AURKB; TP53; TP53 |
NA: NA | Geographic retinal atrophy | NA | APP |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CAMK2B; MAOA; ACHE; SLC6A2; CYP3A4 |
A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | PKM; MMP13; ACHE; PTGS1; PTGS2; PTGS2; PTGS2; PTGS2; IGF1R; INSR; CDK1; SLC6A2; ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | SRC; ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | INSR |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; PIK3CG; PIK3CG; PTGS2; INSR; NFKB1; GPBAR1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
C00-D49: Neoplasms | Renal cancer | C64 | CA9; KDR |
C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; KDR; KDR |
J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP |
G00-G99: Diseases of the nervous system G00-G99 | Amyotrophic lateral sclerosis | G12.2 | BCL2 |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | INSR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperglycaemia in type 2 diabetes | E11, R73.9 | INSR |
Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA; SLC6A2 |
G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1; MMP9 |
C00-D49: Neoplasms | AML | NA | FLT3; KDR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B; ALOX5; SYK |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; GSK3B; MAPT; ACHE; ACHE; ACHE; PTGS2; INSR; APP |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | PIK3CG; KDR |
N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | INSR; ESR1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
NA: NA | Angioedema | NA | PIK3CG |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; PIK3CG; PIK3CG |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | AKT1; PIK3CG |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SYK; SRC; CD38; AURKB; TP53 |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; MMP13; MMP3; MMP2; PTGS1; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2 |
J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MPO; ALOX5; MAPK14 |
C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | SYK; BCL2 |
H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1 |
N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS1; PTGS2; PTGS2; PTGS2; PTGS2; ESR1 |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA1; CA2; MYLK |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; ESR1; ESR1 |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT; ACHE |
C00-D49: Neoplasms | CLL | NA | FLT3 |
C00-D49: Neoplasms | Lymphoma | C81-C86 | AKT1; PIK3CG; PIK3CG; CA9; INSR; HIF1A; BCL2 |
H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET |
C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
NA: NA | Acute respiratory distress syndrome | NA | MAPK14 |
C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC; CYP19A1 |
C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5; PTGS1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; GSK3B; PTPN1; INSR |
C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1 |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2; PTGS1; ESR1 |
I00-I99: Diseases of the circulatory system | Acute coronary syndrome | I74 | MAPK14 |
C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |
C00-D49: Neoplasms | Leukemia | C90-C95 | AKT1; FLT3; BCL2; ESR1 |
A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
J00-J99: Diseases of the respiratory system | Acute lung injury | J80 | MAPK14 |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH; SLC6A2 |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; TP53; KDR; KDR |
A00-B99: Certain infectious and parasitic diseases | HCV infection | B17.1, B18.2 | MMP3 |
K00-K95: Diseases of the digestive system | Crohn's disease | K50 | INSR |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
C00-D49: Neoplasms | Breast cancer | C50 | PIK3CG; FLT3; FLT3; CA9; NQO2; IGF1R; INSR; CYP19A1; CDK1; BCL2; ESR1; ESR1; KDR; KDR; KDR |
I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | PIK3CG; MMP3 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Myocardial reperfusion injury | T86.4 | AKT1 |
I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | SRC |
N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
NA: NA | Joint and muscular pain | NA | PTGS2 |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | SLC6A2 |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
C00-D49: Neoplasms | Diffuse large B-cell lymphoma | C83.3 | PIK3CG |
J00-J99: Diseases of the respiratory system | Asthma | J45 | PLA2G1B; ALOX5; ALOX5; SYK; SYK; PTGS2 |
C00-D49: Neoplasms | Cancer | C00-C96 | AKT1; MET; GSK3B; CSNK2A1; SYK; PIK3CA; PIK3CG; CA1; FLT3; FLT3; CA9; MMP2; NQO2; ACHE; PTGS2; SRC; IGF1R; CD38; HIF1A; CDK1; MAPK1; MAPK14; MMP9; NFKB1; PIM1; CDC25B; PTK2; BCL2; BCL2; TP53; PIK3CB; ESR1; ESR1; KDR; APP |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cancer pain | R52, G89 | SLC6A2 |
C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1 |
NA: NA | Inflammatory diseases | NA | MAPK14 |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MPO; PLA2G1B; ALOX5; MMP13; SYK; PIK3CG; PTGS1; PTGS2; MAPK14 |
K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS1; PTGS2; MAPK14 |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; ABCC1; ABCC1; PTGS2; XDH |
NA: NA | Gonorrheal vaginitis | NA | ESR1 |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; CA1; CA1; ACHE |
NA: NA | GIST | NA | FLT3 |
C00-D49: Neoplasms | Glioblastoma multiforme | C71 | SRC |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA4; CA2 |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; APP |
G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
C00-D49: Neoplasms | Endometrial cancer | C54.1 | PIK3CG; PIK3CG |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PTGS2; CYP19A1 |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
NA: NA | Edema | NA | CA2 |
C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; KDR; KDR; KDR; KDR |
C00-D49: Neoplasms | Advanced melanoma | C43 | BCL2 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | GPBAR1 |
C00-D49: Neoplasms | Metastasis | C00-C97 | AXL |
N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
C00-D49: Neoplasms | Mesothelioma | C45 | PTK2 |
C00-D49: Neoplasms | Pancreatic cancer | C25 | AKT1; FLT3; MMP2; PTGS2; KDR |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
E00-E89: Endocrine, nutritional and metabolic diseases | Hunter syndrome | E76.1 | INSR |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; ESR1; APP |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; PTGS1; PTGS2; PTGS2 |
C00-D49: Neoplasms | Neuroblastoma | C74.1, C74.9, C75.4, C75.5, D35.0, D35.5, D35.6, D44.6, D44.7 | SLC6A2 |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; ACHE |
C00-D49: Neoplasms | Neuroendocrine cancer | C7A | SLC6A2 |
NA: NA | Menopausal disorder | NA | ESR1 |
C00-D49: Neoplasms | Melanoma | C43 | KDR; KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA |